TY  - JOUR
A1  - Sürün, Duran
A1  - Melchner, Harald von
A1  - Schnütgen, Frank
T1  - CRISPR/Cas9 genome engineering in hematopoietic cells
T2  - Drug discovery today. Technologies
N2  - The development of genome editing tools capable of modifying specific genomic sequences with unprecedented accuracy has opened up a wide range of new possibilities in targeted gene manipulation. In particular, the CRISPR/Cas9 system, a repurposed prokaryotic adaptive immune system, has been widely adopted because of its unmatched simplicity and flexibility.
In this review we discuss achievements and current limitations of CRISPR/Cas9 genome editing in hematopoietic cells with special emphasis on its potential use in ex vivo gene therapy of monogenic blood disorders, HIV and cancer.
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/51401
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-514012
SN  - 1740-6749
N1  - © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
VL  - 28
SP  - 33
EP  - 39
PB  - Elsevier
CY  - Amsterdam [u.a.]
ER  -